Switching to E-cigarettes in African-American Smokers

Description

The objectives of this application are to 1) compare short- and long-term harm reduction and abuse liability potential of a nicotine salt pod-based electronic cigarettes (EC) in African American (AA) exclusive EC, dual cig-EC, and exclusive cig users, 2) characterize factors that predict who switches fully, partially, or not at all, and 3) examine if harm reduction can be further enhanced by treating dual users with varenicline (VAR) to eliminate cigarette smoking.

Conditions

Smoking Reduction

Study Overview

Study Details

Study overview

The objectives of this application are to 1) compare short- and long-term harm reduction and abuse liability potential of a nicotine salt pod-based electronic cigarettes (EC) in African American (AA) exclusive EC, dual cig-EC, and exclusive cig users, 2) characterize factors that predict who switches fully, partially, or not at all, and 3) examine if harm reduction can be further enhanced by treating dual users with varenicline (VAR) to eliminate cigarette smoking.

4th Generation E-cigarettes in African American Smokers: Reducing Harm and Quitting Combustible Cigarettes in Dual Users

Switching to E-cigarettes in African-American Smokers

Condition
Smoking Reduction
Intervention / Treatment

-

Contacts and Locations

Kansas City

Swope Health Central, Kansas City, Missouri, United States, 64130

Kansas City

University of Kansas Medical Center, Kansas City, Missouri, United States, 64130

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

For general information about clinical research, read Learn About Studies.

Eligibility Criteria

  • * African American
  • * ≥ 21 years of age
  • * Smoke \>5 cigarettes per day
  • * Smoked cigarettes for \> 6 months
  • * Verified smoker (CO \> 5 ppm)
  • * Functioning telephone
  • * Interested in switching to EC
  • * Willing to take varenicline and complete all study visits
  • * Interested in quitting smoking
  • * Use of smoking cessation pharmacotherapy in the month prior to enrollment
  • * Use of other tobacco products in past 30 days (i.e., cigarillos, cigars, hookah, smokeless tobacco, pipes)
  • * EC use on \> 4 of the past 30 days
  • * Uncontrolled hypertension: BP \> 180 (systolic) or \> 105 (diastolic)
  • * Heart-related event in the past 30 days
  • * Medical contraindications to VAR: unstable cardiac condition (e.g., unstable angina or AMI) cardiac event, or stroke in the past 4 weeks; renal impairment; history of clinically significant allergic reactions; history of epilepsy or seizure disorder; hospitalized for psychiatric issue in past 30 days; active suicidal ideation
  • * Pregnant, contemplating getting pregnant, or breastfeeding
  • * Plans to move from Kansas City metro area during the treatment and follow-up phase
  • * Another household member enrolled in the study

Ages Eligible for Study

21 Years to

Sexes Eligible for Study

ALL

Accepts Healthy Volunteers

Yes

Collaborators and Investigators

University of Kansas Medical Center,

Nicole Nollen, PhD, PRINCIPAL_INVESTIGATOR, University of Kanas Medical Center

Study Record Dates

2027-01-30